Increased Glycated Hemoglobin but Decreased Cholesterol after a Loss of Helicobacter pylori Infection: A Community-Based Longitudinal Metabolic Parameters Follow-Up Study
1
Department of Gastroenterology and Hepatology, Chang-Gung Memorial Hospital and University, Keelung Branch, Keelung 204, Taiwan
2
Community Medicine Research Center, Chang-Gung Memorial Hospital and University, Keelung Branch, Keelung 204, Taiwan
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2021, 11(10), 997; https://doi.org/10.3390/jpm11100997
Submission received: 29 August 2021
/
Revised: 25 September 2021
/
Accepted: 28 September 2021
/
Published: 30 September 2021
Abstract
:This study aimed to evaluate the impact of Helicobacter pylori (H. pylori) infection on metabolic parameters in a longitudinal follow-up manner. From August 2013 to August 2019, a community-based prospective study of H. pylori and metabolic syndrome (MetS) was performed in the northeastern region of Taiwan. A total of 1865 subjects were divided into four groups according to the serial results of urea breath test (UBT): new H. pylori infection (group 1, n = 41), null H. pylori infection (group 2, n = 897), loss of H. pylori infection (group 3, n = 369), and persistent H. pylori infection (group 4, n = 558). When comparing the subjects between groups 1 and 2, HBA1c was associated with a new H. pylori infection. Body mass index (BMI) was associated with a loss of H. pylori when comparing subjects between groups 3 and 4. Elevated HBA1c and high-density lipoprotein (HDL) levels but lower values of cholesterol and white blood cells (WBCs) were found during serial analyses within group 3. Conclusively, HBA1c was associated with a new H. pylori infection. BMI was associated with H. pylori loss. Increased HBA1c and HDL values but decreased values of cholesterol and WBC were associated with a loss of H. pylori infection.
1. Introduction
Helicobacter pylori (H. pylori) infection is the most common chronic bacterial infection in humans. Serologic evidence of H. pylori infection is uncommon in children before age 10 but rises to 10% in adults between 18 and 30 years of age, and further increases to 50% in those age 60 or older [1,2]. H. pylori infection induces local inflammation in the stomach and a systemic immune reaction in the whole body [3]. The actions of the virulence factors of H. pylori include flagella, urease, lipopolysaccharides, adhesins to stimulate Lewis x antigen, type IV secretion of CagA and exotoxin of Vac A, lytic enzymes, and heat shock proteins [3]. Some immune related cells, such as mast cell, macrophage, and T-cell, are involved in H. pylori infected reaction. Mast cells were abundant in the mucosa of antral gastritis and had a positive correlated with polymorphonuclear and mononuclear cell infiltration [4,5]. H. pylori infection is associated with increased expression of the macrophage migratory inhibitory factor (MIF) protein and MIF mRNA in gastric epithelial and inflammatory cells; along with other cytokines, MIF may play a significant role in gastric inflammation [6]. T cell (e.g., Th1 cell) activation by H. pylori infection may contribute to more severe inflammatory condition [3]. Elevated levels of inflammatory cytokines, such as interleukin 1, 8, 17, tumor necrosis factor α (TNF-α), and lowered levels of leptin are involved in these inflammatory reactions [3,7,8]. A leptin deficiency and high levels of inflammatory cytokines are the critical mechanisms for insulin resistance (IR) and metabolic syndrome (MetS) [8,9,10,11]. H. pylori infection-related extragastric diseases, such as IR, dyslipidemia, obesity, and MetS have been reported [3,12,13,14]. Our previous studies revealed subjects aged less than 50 y/o with H. pylori infection increased a risk of being obesity (BMI ≥ 30) (Odd ratio, OR = 1.836), IR (OR = 12.683), and MetS (OR = 3.717) compared to those without H. pylori infection [2,15].
The hypothesis in this study was that a new infection or a loss of H. pylori infection might change the local gastric and systemic immune reaction, which would influence the metabolic parameters, such as sugar, lipids, and weight during the follow-up period. The individuals without a change in the H. pylori infection status served as the control group. This prospective, community-based study aimed to evaluate the differences in the metabolic parameters between subjects with or without H. pylori infection (intergroup analysis) and the change in metabolic parameters within a new infection or a loss of infection of H. pylori (intragroup analysis).
2. Materials and Methods
This study was a community-based survey for H. pylori and MetS in adults, performed in the northeastern region of Taiwan from August 2013 to August 2019. Participants from the four districts of Anle (metropolis), Gongliao (rural area), Ruifang (mountain city), and Wanli (fishing village) were included. The inclusion criteria were individuals 30 years or older because MetS is mostly diagnosed in middle-aged people or older (>30 years old) and due to ethical considerations [16]. The exclusion criteria were pregnancy or lack of adequate follow-up data, including lesser than four follow-up urea breath tests (UBT) and blood tests. All subjects participated in a demographic survey, physical examination, blood tests, and underwent a UBT for H. pylori infection survey annually. The demographic survey assessed the history of systemic or malignant diseases, such as hypertension (HTN), diabetes mellitus (DM), hyperlipidemia, hematologic disorders, medication history, and family history. Medications, such as proton pump inhibitors or histamine 2 blocker agents, were suspended at least for 14 days before UBT. Physical examination included heart rate, blood pressure, body weight, body height, and waist girth (circumference). The body mass index (BMI, kg/m2) was calculated as the weight (kg) divided by squared height (m). The subjects were asked to fast overnight before drawing the blood samples. Blood tests included a complete blood cell count; metabolic parameters, including fasting sugar, total cholesterol, triglyceride, high density lipoprotein (HDL), glycated hemoglobin (HbA1C), insulin levels, and C-reactive protein (CRP) levels. The blood samples were analyzed within 4 h after collection. The Institutional Review Board of the Chang-Gung Memorial Hospital approved this research (IRB No: 103-3886C). All participants agreed to participate in the study and signed the informed consent form before enrollment.
2.1. Urea Breath Test
The C13-UBT was performed after an overnight fast using the Proto Pylori kit (Isodiagnostika, Canada) containing 75 mg of C13-urea and additives. The subjects were defined as new H. pylori infection when the serial UBT results were negative, negative, positive, and positive (new infection group). Likewise, the subjects were defined as “loss of H. pylori infection” when the serial UBT results were positive, positive, negative, and negative (loss of infection group). The subjects who showed consistent results of UBT, such as “positive, positive, positive, positive” or “negative, negative, negative, negative,” were defined as “persistent infection group” or “no infection group.” Because there was no other test except UBT to confirm the status of H. pylori infection in this study, subjects with only one positive or only one negative result, inconsistent results, such as positive, negative, negative, positive or negative, positive, positive, negative, in the serial four UBT were excluded.
2.2. Metabolic Syndrome
A race-specific waist girth threshold based on the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III criteria were used to prevent distortions in the MetS prevalence [17]. The cut-off values for a normal waist circumference in Asian men and women were set to 90 cm (35.4 inches) and 80 cm (31.5 inches), respectively.
2.3. Risk Factors of H. pylori Infection
H. pylori infection’s risk factors include age, socioeconomic status, urban-dwelling (different districts), number of family members, and the level of education [18].
2.4. Data Analysis and Statistics
For continuous variables, the values are expressed as mean ± standard deviation (SD). A t-test was applied to compare the mean values of two independent samples. A paired sample t-test was applied for a repeated measures analysis within the same sample. A one-way ANOVA was used to compare the mean values of multiple samples. The categorical data were analyzed using the Chi-squared test or Fisher’s exact test, as appropriate. A case-control matched analysis by propensity score was used in this observational study to reduce the selection bias. All the statistical tests were two-tailed. A p-value of <0.05 was considered to be statistically significant. A logistic regression analysis was applied for the odds ratio (OR) of a new onset of H. pylori infection when comparing the subjects with a new H. pylori infection to subjects without an H. pylori infection. Likewise, the OR of a loss of H. pylori infection was analyzed when comparing subjects with a new onset of H. pylori infection in subjects with a persistent H. pylori infection. First univariate regression analysis was performed for candidate factors, then multivariate regression analysis was performed for selective factors. A repeated test from stored serum would be performed for the management of missing data.
Statistical analyses were performed using PASW for Windows (version 18.0, SPSS Inc., Chicago, IL, USA).
3. Results
The patients were divided into four groups: new H. pylori infection group (group 1, n = 41), null H. pylori infection group (group 2, n = 897), loss of H. pylori infection group (group 3, n = 369), and persistent H. pylori infection group (group 4, n = 558) (Figure 1). Table 1 shows the demographics of these four groups. When comparing the subjects between groups 1 and 2, older age (>60 years), living in Wanli district, and having more family members (6–10) were found in group 1 (new H. pylori infection) (p < 0.05).
There was no difference in the age, gender, districts¸ education level distributions, and number of family members between the subjects of groups 3 and 4. Among 369 subjects in group 3 (loss of H. pylori infection), 186 (50.4%) subjects had received H. pylori eradication therapy, and 143 (38.8%) subjects had received endoscopic studies at our hospital.
When comparing the subjects with and without new H. pylori infections (group 1 vs. group 2), baseline HBA1c was observed to be associated with new H. pylori infections (adjust odds ratio, aOR = 1.338, 95% CI: 1.034—1.731, p < 0.027, adjusting the confounding factors of age and gender) (Table 2).
When comparing the subjects with and without loss of H. pylori infection (group 3 vs. group 4), the baseline body weight (aOR = 1.019, 95% CI: 1.004–1.034, p < 0.013) and BMI (aOR = 1.068, 95% CI: 1.027–1.109, p < 0.001) were associated with the loss of H. pylori infection. Table 3 shows the intragroup parameter changes in Groups 1–4 by the paired t-test (Table 3).
In group 3 (loss of H. pylori infection), elevated HbA1C and HDL values were found (mean delta change of HBA1c = 0.123, p < 0.014; mean delta change of HDL = 2.028, p < 0.001). However, lowered values of WBC and cholesterol were detected (mean delta change of WBC = −0.281, p < 0.001; mean delta change of Cholesterol = −6.723, p < 0.001) (Table 3). Among groups 1, 2, and 4, no significant differences in the values were found. In group 4 (persistent H. pylori infection), a more increased HBA1c (mean delta change = 0.327, p < 0.003) was found when compared subjects in group 3.
For the common diseases including DM, HTN, dyslipidaemia, CKD, and MetS, no significant difference in the disease status (new onset or a loss of disease) was found between those with or without a change in the H. pylori infection within the four years of follow-up (Table 4).
4. Discussion
Most individuals experience H. pylori infection during childhood, and the infection rate increases with age [1]. This increased prevalence of infection with age was initially thought to represent a continuing acquisition throughout adulthood. However, new infection or reinfection in adults is quite uncommon, especially in developed countries, where it is estimated to occur in less than 0.5% of cases per year [19]. Demographic factors, such as old age, number of family members, and district differences were related to a new H. pylori infection in the present study, when compared to subjects without new H. pylori infections.
In the current study, glycated hemoglobin (HBA1c) is observed to be associated with new H. pylori infections among subjects without prior H. pylori infections. HBA1c results from hemoglobin glycosylation, reflecting integrated blood glucose levels during the preceding three months [20]. Previous studies revealed an association between a post-H. pylori infection status and insulin resistance or glycated hemoglobin [12,20,21]. However, there are no reports regarding the relationship between serum HBA1c levels and new H. pylori infection. The present study demonstrated that HBA1c is associated with a new H. pylori infection (OR = 1.338, 95% CI: 1.034–1.731, p < 0.027). A possible explanation is that a high blood glucose level results in immune dysfunction and gastrointestinal dysmotility, which increases the vulnerability to an infection in the stomach [22]. In one study, young patients with diabetes presented a higher risk of H. pylori reinfection following previous successful H. pylori eradication [23].
The current study revealed that weight and BMI were associated with a loss of H. pylori infection. This observation may be not a causality result. In this study, we found subjects with high body weight and BMI had more hospital visits for underlying diseases. During outpatient clinics, they might have additional chances for gastrointestinal referrals and receiving H. pylori eradication therapy.
Boyuk et al. reported no associations between H. pylori presence and inflammatory response, which was evaluated by neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) measurements in patients with dyspepsia [24]. They though H. pylori infection might not be related to the chronic inflammatory response. But our prospective study revealed a decreased WBC in follow up data among those loss of H. pylori infection. A further prospective study is required to clarify the change of NLR or PLR and the relationship between these inflammatory changes and gastric malignant formation.
Although several studies have reported the associations between IR, MetS, CKD, or dyslipidemia, and H. pylori infections, these extra-gastric diseases are not recommended for routine checkups of H. pylori infection and treatment according to current guidelines [3,25,26]. Our study further demonstrated that a change in the H. pylori infection status was not associated with new onset or a loss of some common diseases, such as DM, HTN, dyslipidemia, CKD, and MetS. The influence of H. pylori eradication on glucose or lipid control has been controversial in previous studies [27,28,29,30]. The current study revealed that a loss of H. pylori infection would increase the value of HDL and HBA1c but decrease the values of cholesterol and WBC. Some studies reported the impact of gut microbiota change on the metabolic parameter following H. pylori eradiation therapy [31,32]. These changes of metabolic parameters may have only minor influence on the progression or resolution of diseases, such as DM, HTN, or CKD within four years of follow-up.
Because of the increasing antibiotic resistance of H. pylori, the eradication rate of clarithromycin-based triple therapy has decreased below 80% [3,33]. Other combinations for eradication therapy, such as concomitant therapy, hybrid and high dose dual therapy have all been used as first-line therapies [34,35]. Some gastrointestinal symptoms, such as reflux symptoms, maldigestion or abdominal pain, and hematologic diseases, such as iron deficiency or thrombocytopenia purpura, may be relieved after eradication therapy [36]. To overcome the varying potency of PPIs interfered by CYP2C19 genotypes, several studies used a potassium-competitive acid blocker, P-CAB, such as vonoprazan for H. pylori eradication combination therapy [37].
This study has a few limitations. First, a selection bias may be present. Our study originated from a community-based survey for MetS. Although the data collected from the community subjects might be nearer the real-world condition, the participants in our study were older (mean age > 50 years) and female predominant (more than 60%). The participants may consist of older adults with underlying diseases and a desire for medical examinations. Second, several subjects did not complete the four UBT follow-ups. Some participants declined a follow-up UBT, especially when a negative result of UBT was found in previous studies. The other participants had inconsistent UBT results (unsure H. pylori infection status) were excluded for analyses. Third, a few subjects who took antibiotics from other hospitals might recall as no antibiotic usage on questionnaire screening. The number of cases of spontaneous loss of H. pylori infection might be overestimated.
5. Conclusions
HBA1c was associated with a new H. pylori infection (OR = 1.338). Weight and BMI were associated with a loss of H. pylori infection (OR = 1.019 and 1.068, respectively). By intra-group analysis, increased values of HBA1c and HDL but decreased values of cholesterol and WBC were detected among subjects with a loss of H. pylori infection. However, the progression of diseases such as DM, HTN, CKD, dyslipidemia, and MetS were not different after the changes in H. pylori infection status within four years of follow-up.
Author Contributions
L.-W.C. and R.-N.C. provided the study concept and design. L.-W.C., C.-H.C. and C.-L.L. collected data. L.-W.C. performed data analysis and interpretation. L.-W.C. and R.-N.C. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.
Funding
This research was funded by Chang Gung Memorial Hospital (CRRPG2H0052, CLRPG2J0011).
Institutional Review Board Statement
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Institutional Review Board of the Chang-Gung Memorial Hospital approved this research (IRB No. 103-3886C).
Informed Consent Statement
All participants agreed to the study conditions and provided informed consent.
Acknowledgments
This study was supported by Chang-Gung Memorial Hospital Research Project (No. CRRPG2H0052 and CLRPG2J0011). Authors thank Mi-Sio Huang for collecting data.
Conflicts of Interest
The authors have no competing interest as defined by Nature Research, or other interest that might be perceived to influence the results and/or discussion reported in this paper.
References
- Kivi, M.; Tindberg, Y. Helicobacter pylori occurrence and transmission: A family affair? Scand. J. Infect. Dis. 2006, 38, 407–417. [Google Scholar] [CrossRef] [PubMed]
- Chen, L.W.; Chien, C.Y.; Yang, K.J.; Kuo, S.F.; Chen, C.H.; Chien, R.N. Helicobacter pylori Infection Increases Insulin Resistance and Metabolic Syndrome in Residents Younger than 50 Years Old: A Community-Based Study. PLoS ONE 2015, 10, e0128671. [Google Scholar] [CrossRef] [PubMed]
- Charitos, I.A.; D’Agostino, D.; Topi, S.; Bottalico, L. 40 Years of Helicobacter pylori: A Revolution in Biomedical Thought. Gastroenterol. Insights 2021, 12, 11. [Google Scholar] [CrossRef]
- Santacroce, L.; Bufo, P.; Latorre, V.; Losacco, T. Role of mast cells in the physiopathology of gastric lesions caused by Helicobacter pylori. Chir. Ital. 2000, 52, 527–531. [Google Scholar] [PubMed]
- Mysorekar, V.V.; Dandekar, C.P.; Prakash, B.S. Mast cells in Helicobacter pylori associated antral gastritis. Indian J. Pathol. Microbiol. 2003, 46, 605–609. [Google Scholar] [PubMed]
- Xia, H.H.; Lam, S.K.; Huang, X.R.; Wong, W.M.; Leung, S.Y.; Yuen, S.T.; Lan, H.Y.; Wong, B.C. Helicobacter pylori infection is associated with increased expression of macrophage migratory inhibitory factor--by epithelial cells, T cells, and macrophages--in gastric mucosa. J Infect Dis. 2004, 190, 293–302. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Noach, L.A.; Bosma, N.B.; Jansen, J.; Hoek, F.J.; van Deventer, S.J.; Tytgat, G.N. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand. J. Gastroenterol. 1994, 29, 425–429. [Google Scholar] [CrossRef]
- Breidert, M.; Miehlke, S.; Glasow, A.; Orban, Z.; Stolte, M.; Ehninger, G.; Bayerdörffer, E.; Nettesheim, O.; Halm, U.; Haidan, A.; et al. Leptin and its receptor in normal human gastric mucosa and in Helicobacter pylori-associated gastritis. Scand. J. Gastroenterol. 1999, 34, 954–961. [Google Scholar]
- Hotamisligil, G.S.; Shargill, N.S.; Spiegelman, B.M. Adipose expression of tumor necrosis factoralpha: Direct role in obesity-linked insulin resistance. Science 1993, 259, 87–91. [Google Scholar] [CrossRef]
- Cohen, B.; Novick, D.; Rubinstein, M. Modulation of insulin activities by leptin. Science 1996, 274, 1185–1188. [Google Scholar] [CrossRef]
- Ferrannini, E.; Haffner, S.M.; Mitchell, B.D.; Stern, M.P. Hyperinsulinaemia: The key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991, 34, 416–422. [Google Scholar] [CrossRef]
- Gunji, T.; Matsuhashi, N.; Sato, H.; Fujibayashi, K.; Okumura, M.; Sasabe, N.; Urabe, A. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am. J. Gastroenterol. 2008, 103, 3005–3010. [Google Scholar] [CrossRef] [PubMed]
- Gunji, T.; Matsuhashi, N.; Sato, H.; Fujibayashi, K.; Okumura, M.; Sasabe, N.; Urabe, A. Helicobacter pylori infection significantly increases insulin resistance in the asymptomatic Japanese population. Helicobacter 2009, 14, 144–150. [Google Scholar] [CrossRef]
- Polyzos, S.A.; Kountouras, J.; Zavos, C.; Deretzi, G. The association between Helicobacter pylori infection and insulin resistance: A systematic review. Helicobacter 2011, 16, 79–88. [Google Scholar] [CrossRef] [PubMed]
- Chen, L.W.; Kuo, S.F.; Chen, C.H.; Chien, C.H.; Lin, C.L.; Chien, R.N. A community-based study on the association between Helicobacter pylori Infection and obesity. Sci. Rep. 2018, 8, 10746. [Google Scholar] [CrossRef]
- Ford, E.S.; Giles, W.H.; Dietz, W.H. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287, 356e9. [Google Scholar] [CrossRef]
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285, 2486–2497. [Google Scholar] [CrossRef] [PubMed]
- Cho, I.; Blaser, M.J.; François, F.; Mathew, J.P.; Ye, X.Y.; Goldberg, J.D.; Bini, E.J. Helicobacter pylori and overweight status in the United States: Data from the Third National Health and Nutrition Examination Survey. Am. J. Epidemiol. 2005, 162, 579–584. [Google Scholar] [CrossRef] [Green Version]
- Rupnow, M.F.; Shachter, R.D.; Owens, D.K.; Parsonnet, J. A dynamic transmission model for predicting trends in Helicobacter pylori and associated diseases in the United States. Emerg. Infect. Dis. 2000, 6, 228–237. [Google Scholar] [CrossRef] [Green Version]
- Buell, C.; Kermah, D.; Davidson, M.B. Utility of A1C for diabetes screening in the 1999–2004 NHANES population. Diabetes Care 2007, 30, 2233–2235. [Google Scholar] [CrossRef] [Green Version]
- Chen, Y.; Blaser, M.J. Association between gastric Helicobacter pylori colonization and glycated hemoglobin levels. J. Infect. Dis. 2012, 205, 1195–1202. [Google Scholar] [CrossRef] [PubMed]
- Casqueiro, J.; Casqueiro, J.; Alves, C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J. Endocrinol. Metab. 2012, 16 (Suppl. 1), S27–S36. [Google Scholar]
- Candelli, M.; Rigante, D.; Schiavino, A.; Gabrielli, M.; Crea, F.; Del Lungo, L.M.; Pignataro, G.; Sacco, E.; Monaco, S.; Gentiloni, S.N.; et al. High reinfection rate of Helicobacter pylori in young type 1 diabetic patients: A three-year follow-up study. Eur. Rev. Med. Pharm. Sci. 2012, 16, 1468–1472. [Google Scholar]
- Boyuk, B.; Saydan, D.; Mavis, O.; Erman, H. Evaluation of Helicobacter pylori infection, neutrophil–lymphocyte ratio and platelet–lymphocyteratioin dyspeptic patients. Gastroenterol. Insights 2020, 11, 2. [Google Scholar] [CrossRef]
- Gravina, A.G.; Zagari, R.M.; De Musis, C.; Romano, L.; Loguercio, C.; Romano, M. Helicobacter pylori and extragastric diseases: A review. World J. Gastroenterol. 2018, 24, 3204–3221. [Google Scholar] [CrossRef]
- Franceschi, F.; Covino, M.; Roubaud Baudron, C. Review: Helicobacter pylori and extragastric diseases. Helicobacter 2019, 24 (Suppl. 1), e12636. [Google Scholar] [CrossRef] [Green Version]
- Park, S.H.; Jeon, W.K.; Kim, S.H.; Kim, H.J.; Park, D.I.; Cho, Y.K.; Sung, I.K.; Sohn, C.I.; Kim, B.I.; Keum, D.K. Helicobacter Pylori eradication has no effect on metabolic and inflammatory parameters. J. Nat. Med. Assoc. 2005, 97, 508–513. [Google Scholar]
- Kanbay, M.; Gur, G.; Yucel, M.; Yilmaz, U.; Boyacioglu, S. Does Eradication of Helicobacter pylori Infection Help Normalize Serum Lipid and CRP Levels? Dig. Dis. Sci. 2005, 50, 1228–1231. [Google Scholar] [CrossRef]
- Longo-Mbenza, B.; Nkondi Nsenga, J.; Vangu Ngoma, D. Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by Helicobacter pylori infection and treated by antibiotics. Int. J. Cardiol. 2007, 18, 229–238. [Google Scholar] [CrossRef]
- Gen, R.; Demir, M.; Ataseven, H. Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation. South. Med. J. 2010, 103, 190–196. [Google Scholar] [CrossRef]
- Martín-Núñez, G.M.; Cornejo-Pareja, I.; Roca-Rodríguez, M.; Clemente-Postigo, M.; Cardona, F.; Fernández-García, J.C.; Moreno-Indias, I.; Tinahones, F.J. H. pylori eradication treatment causes alterations in the gut microbiota and blood lipid levels. Front. Med. 2020, 7, 417. [Google Scholar] [CrossRef] [PubMed]
- Liou, J.Y.; Chen, C.H.; Chang, C.H.; Fang, Y.U.; Bair, M.I.; Chen, P.O.; Chang, C.H.; Hsu, Y.A.; Chen, M.E.; Chen, C.H.; et al. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: A multicentre, open-label, randomised trial. Lancet Infect. Dis. 2019, 19, 1109–1120. [Google Scholar] [CrossRef]
- Malfertheiner, P.; Megraud, F.; O’Morain, C.A.; Atherton, J.; Axon, A.T.R.; Bazzoli, F.; Gensini, G.F.; Gisbert, J.P.; Graham, D.Y.; Rokkas, T. Management of Helicobacter pylori infection: The Maastricht IV/Florence Consensus Report. Gut 2012, 61, 646–664. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mestrovic, A.; Bozic, J.; Vukojevic, K.; Tonkic, A. Impact of Different Helicobacter pylori Eradication Therapies on Gastrointestinal Symptoms. Medicina 2021, 57, 803. [Google Scholar] [CrossRef] [PubMed]
- Chen, L.W.; Chang, L.C.; Hua, C.C.; Liu, C.J.; Chou, T.S.; Lin, C.L.; Chien, R.N. The Application of High-Dose Proton Pump Inhibitor Induction Treatment before Dual Therapy for Helicobacter pylori Eradication: An Open-Label Random Trial. J. Clin. Med. 2021, 10, 4352. [Google Scholar] [CrossRef]
- IIkuse, T.; Toda, M.; Kashiwagi, K.; Maruyama, K.; Nagata, M.; Tokushima, K.; Ito, N.; Tokita, K.; Kyodo, R.; Hosoi, K.; et al. Efficacy of Helicobacter pylori eradication therapy on platelet recovery in pediatric immune thrombocytopenic purpura-Case series and a systematic review. Microorganisms 2020, 8, 1457. [Google Scholar] [CrossRef]
- Sugimoto, M.; Hira, D.; Murata, M.; Kawai, T.; Terada, T. Effect of antibiotic susceptibility and CYP3A4/5 and CYP2C19 genotype on the outcome of Vonoprazan-containing Helicobacter pylori eradication therapy. Antibiotics 2020, 9, 645. [Google Scholar] [CrossRef]
Figure 1.
Study diagram.
Table 1.
Demography.
| Group 1 | Group 2 | Group 3 | Group 4 | p Value | |
|---|---|---|---|---|---|
| Number | 41 | 897 | 369 | 558 | |
| Age | 62.1 ± 10.4 | 54.3 ± 12.2 | 57.8 ± 10.3 | 59.1 ± 11.1 | <0.001 |
| Gender (%) | <0.006 | ||||
| Male | 13 (31.7) | 256 (28.5) | 112 (30.4) | 208 (37.3) | |
| Female | 28 (68.3) | 641 (71.5) | 257 (69.6) | 350 (62.7) | |
| Age Group (%) | <0.001 | ||||
| 30–39 | 1 (2.4) | 145 (16.2) | 24 (6.5) | 27 (4.8) | |
| 40–49 | 3 (7.3) | 147 (16.4) | 43 (11.7) | 78 (14.0) | |
| 50–59 | 11 (26.8) | 277 (30.9) | 134 (36.3) | 173 (31.0) | |
| 60–69 | 14 (34.1) | 238 (26.5) | 126 (34.1) | 183 (32.8) | |
| 70+ | 12 (29.3) | 90 (10.0) | 42 (11.4) | 97 (17.4) | |
| District (%) | <0.001 | ||||
| Anle | 25 (61.0) | 608 (67.8) | 215 (58.3) | 307 (55.0) | |
| Gongliao | 2 (4.9) | 78 (8.7) | 45 (12.2) | 52 (9.3) | |
| Ruifang | 2 (4.9) | 94 (10.5) | 62 (16.8) | 107 (19.2) | |
| Wanli | 12 (29.2) | 117 (13.0) | 47 (12.7) | 92 (16.5) | |
| Education Level (%) | <0.001 | ||||
| Illiterate | 5 (12.2) | 46 (5.1) | 30 (8.2) | 55 (9.8) | |
| Primary school | 11 (26.8) | 194 (21.6) | 102 (27.6) | 146 (26.2) | |
| Junior high school | 8 (19.5) | 138 (15.4) | 60 (16.3) | 105 (18.8) | |
| Senior high school | 14 (34.1) | 264 (29.4) | 121 (32.8) | 154 (27.6) | |
| College | 3 (7.3) | 224 (25.0) | 54 (14.6) | 89 (15.9) | |
| Graduate school | 0 (0.0) | 31 (3.5) | 2 (0.5) | 9 (1.6) | |
| Family member (%) | <0.025 | ||||
| 1–5 | 34 (82.9) | 858 (95.7) | 350 (94.9) | 525 (94.1) | |
| 6–10 | 7 (17.1) | 34 (3.8) | 19 (5.1) | 30 (5.4) | |
| 11–15 | 0 | 5 (0.5) | 0 | 3 (0.5) |
Group 1: a new onset of getting H. pylori infection; Group 2: no H. pylori infection; Group 3: a new onset of losing H. pylori infection; Group 4: a persist H. pylori infection.
Table 2.
Factors associated with H. pylori infection status change by logistical regression analysis.
Table 2.
Factors associated with H. pylori infection status change by logistical regression analysis.
| A New H pylori Infection (Group 1 vs. Group 2) | ||||||
|---|---|---|---|---|---|---|
| Univariate | Multivariate | |||||
| Parameter | aOR | 95% CI | p-Value | aOR | 95% CI | p-Value |
| waist | 1.013 | (0.983, 1.045) | 0.403 | |||
| BMI | 1.039 | (0.956, 1.128) | 0.372 | 1.016 | (0.905, 1.037) | 0.463 |
| FBG | 1.006 | (0.993, 1.020) | 0.339 | |||
| HBA1c | 1.338 | (1.034, 1.731) | <0.027 | 1.470 | (1.045, 1.851) | <0.021 |
| Triglyceride | 1.001 | (0.997, 1.006) | 0.537 | |||
| Cholesterol | 0.998 | (0.990, 1.005) | 0.518 | |||
| HS CRP | 0.936 | (0.776, 1.129) | 0.487 | |||
| WBC | 1.124 | (0.906, 1.394) | 0.289 | |||
| A loss H pylori infection (Group 3 vs. Group 4) | ||||||
| Univariate | Multivariate | |||||
| Parameter | aOR | 95% CI | p-Value | aOR | 95% CI | p-Value |
| waist | 1.011 | (0.995, 1.027) | 0.196 | |||
| BMI | 1.068 | (1.027, 1.109) | <0.001 | 1.274 | (1.154, 1.376) | <0.001 |
| FBG | 1.004 | (0.999, 1.009) | 0.131 | |||
| HBA1c | 0.908 | (0.797, 1.036) | 0.151 | 1.049 | (0.845, 1.161) | 0.233 |
| Triglyceride | 1.000 | (0.998, 1.002) | 0.911 | |||
| Cholesterol | 0.999 | (0.995, 1.003) | 0.600 | |||
| HS CRP | 0.977 | (0.929, 1.027) | 0.355 | |||
| WBC | 0.948 | (0.861, 1.043) | 0.272 | |||
aOR: adjusted odds ratio, after adjusting factors of age and gender; FBG: fasting blood glucose; WBC: white blood cell; HS CRP: high sensitive C-reactive protein; HBA1C: glycated hemoglobin; BMI: body mass index.
Table 3.
Intragroup mean values change after a different infection status of H. pylori.
| A New H. pylori Infection (Group 1) | A Loss of H. pylori Infection (Group 3) | |||||
|---|---|---|---|---|---|---|
| Parameter | Mean † | T | p-Value | Mean | T | p-Value |
| weight | −0.131 | −0.546 | 0.586 | −0.100 | −0.805 | 0.422 |
| waist | −1.031 | −1.904 | 0.060 | 0.447 | 1.733 | 0.084 |
| FBG | −3.531 | −1.723 | 0.089 | 1.169 | 0.792 | 0.429 |
| HBA1c | 0.011 | 0.050 | 0.960 | 0.123 | 2.477 | <0.014 |
| Triglyceride | −4.383 | −0.688 | 0.493 | 0.757 | 0.224 | 0.823 |
| Cholesterol | −1.321 | −0.425 | 0.672 | −6.723 | −3.746 | <0.001 |
| HDL | 1.510 | 1.210 | 0.230 | 2.028 | 4.378 | <0.001 |
| LDL | −0.843 | −0.309 | 0.758 | −0.375 | −0.248 | 0.804 |
| WBC | 0.023 | 0.201 | 0.841 | −0.281 | −4.184 | <0.001 |
| HS CRP | −0.142 | −0.475 | 0.636 | −0.015 | −0.085 | 0.932 |
| No H. pylori infection (Group 2) | Persist H. pylori infection (Group 4) | |||||
| Parameter | mean | T | p-value | mean | T | p-value |
| weight | 0.023 | 0.127 | 0.899 | −0.503 | −1.360 | 0.176 |
| waist | 0.683 | 1.667 | 0.097 | 0.640 | 0.007 | 0.994 |
| FBG | 0.311 | 0.380 | 0.704 | 0.876 | 0.526 | 0.600 |
| HBA1c | 0.053 | 0.286 | 0.775 | 0.327 | 2.967 | <0.003 |
| Triglyceride | −3.522 | −0.913 | 0.363 | 3.913 | 0.943 | 0.347 |
| Cholesterol | 0.832 | 0.304 | 0.761 | 2.019 | 0.854 | 0.395 |
| HDL | −0.399 | −0.616 | 0.539 | −0.382 | −0.615 | 0.540 |
| LDL | 3.947 | 1.723 | 0.087 | 1.790 | 0.887 | 0.377 |
| WBC | 0.037 | 0.423 | 0.673 | −0.049 | −0.489 | 0.626 |
| HS CRP | 0.138 | 0.677 | 0.499 | −0.021 | −0.032 | 0.975 |
† Mean: the mean of data change (later value minus previous value); FBG: fasting blood glucose; HBA1c: glycated hemoglobin; HDL: high density lipoprotein cholesterol; LDL: low density lipoprotein cholesterol; WBC: white blood cell count; HS CRP: high sensitive C reactive protein.
Table 4.
Impact of H. pylori infection status change on diseases development.
| New H. pylori Infection | Loss H. pylori Infection | |||||
|---|---|---|---|---|---|---|
| Group 1 vs. Group 2 | Group 3 vs. Group 4 | |||||
| Disease | Aor † | 95% CI | p-Value | aOR | 95% CI | p-Value |
| HTN | 1.389 | (0.687, 2.808) | 0.361 | 1.074 | (0.783, 1.472) | 0.658 |
| Dyslipidemia | 0.787 | (0.304, 2.035) | 0.621 | 1.018 | (0.678, 1.529) | 0.931 |
| CKD | 0.737 | (0.332, 1.635) | 0.453 | 1.089 | (0.752, 1.577) | 0.653 |
| MetS | 1.991 | (0.960, 4.128) | 0.064 | 1.231 | (0.895, 1.693) | 0.201 |
| DM | 0.947 | (0.427, 2.099) | 0.894 | 1.174 | (0.812, 1.697) | 0.395 |
† adjusting factors of age, gender; HTN: hypertension; CKD: chronic kidney disease; MetS: metabolic syndrome; DM: diabetic mellitus.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Chen, L.-W.; Chien, C.-H.; Lin, C.-L.; Chien, R.-N. Increased Glycated Hemoglobin but Decreased Cholesterol after a Loss of Helicobacter pylori Infection: A Community-Based Longitudinal Metabolic Parameters Follow-Up Study. J. Pers. Med. 2021, 11, 997. https://doi.org/10.3390/jpm11100997
AMA Style
Chen L-W, Chien C-H, Lin C-L, Chien R-N. Increased Glycated Hemoglobin but Decreased Cholesterol after a Loss of Helicobacter pylori Infection: A Community-Based Longitudinal Metabolic Parameters Follow-Up Study. Journal of Personalized Medicine. 2021; 11(10):997. https://doi.org/10.3390/jpm11100997
Chicago/Turabian StyleChen, Li-Wei, Cheng-Hung Chien, Chih-Lang Lin, and Rong-Nan Chien. 2021. "Increased Glycated Hemoglobin but Decreased Cholesterol after a Loss of Helicobacter pylori Infection: A Community-Based Longitudinal Metabolic Parameters Follow-Up Study" Journal of Personalized Medicine 11, no. 10: 997. https://doi.org/10.3390/jpm11100997
APA StyleChen, L. -W., Chien, C. -H., Lin, C. -L., & Chien, R. -N. (2021). Increased Glycated Hemoglobin but Decreased Cholesterol after a Loss of Helicobacter pylori Infection: A Community-Based Longitudinal Metabolic Parameters Follow-Up Study. Journal of Personalized Medicine, 11(10), 997. https://doi.org/10.3390/jpm11100997
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
